Content about Eli Lilly

April 22, 2014

Eli Lilly on Monday announced that the Food and Drug Administration has approved Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

INDIANAPOLIS — Eli Lilly on Monday announced that the Food and Drug Administration has approved Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. With this approval, Cyramza becomes the first FDA-approved treatment for patients in this setting.

November 18, 2013

Drug maker Actavis hopes to become the first to market with a generic version of a topical testosterone replacement drug marketed by Eli Lilly, Actavis said.

DUBLIN — Drug maker Actavis hopes to become the first to market with a generic version of a topical testosterone replacement drug marketed by Eli Lilly, Actavis said.

The generic drug maker it filed with the Food and Drug Administration for approval of testosterone topical solution in the 30-mg-per-1.5 mL strength, a generic version of Lilly's Axiron. The drug is used as a replacement therapy for deficient or absent testosterone.

November 6, 2013

Many physicians in Asia say more information on managing Type 2 diabetes is needed, according to a new poll.

INDIANAPOLIS — Many physicians in Asia say more information on managing Type 2 diabetes is needed, according to a new poll.

October 21, 2013

The president of Indiana's Manchester University will retire next summer and has named the university's pharmacy dean as her successor.

FORT WAYNE, Ind. — The president of Indiana's Manchester University will retire next summer and has named the university's pharmacy dean as her successor.

The university, based in Fort Wayne, Ind., said Jo Young Switzer would retire on June 30, 2014 and had named EVP and College of Pharmacy dean Dave McFadden as president, effective the day after. Switzer is Manchester University's first female president.

October 3, 2013

Drug Store News has learned that Mary Kelly has been appointed EVP and chief merchandising officer at Rexall Pharma Plus.

MISSISSAUGA, ONTARIO — Drug Store News has learned that Mary Kelly has been appointed EVP and chief merchandising officer at Rexall Pharma Plus. Kelly, who has more than 26 years experience leading business teams in Canada and the United States, joins the company after four years at Shoppers Drug Mart, most recently as EVP, merchandising and category management. Prior to that, Kelly served 17 years at Target in a  variety of key leadership positions in merchandising and pharmacy, and at Revco Drug Stores and Eli Lilly before that.  

July 16, 2013

Men who took an erectile dysfunction drug made by Eli Lilly experienced normal erectile function when taking it once a day as opposed to taking erectile dysfunction treatment on an as-needed basis, according to a new study.

INDIANAPOLIS — Men who took an erectile dysfunction drug made by Eli Lilly experienced normal erectile function when taking it once a day as opposed to taking erectile dysfunction treatment on an as-needed basis, according to a new study.

The study, published in the Journal of Sexual Medicine, found a greater percentage of men who had an incomplete response to as-needed treatment with phosphodiesterase type 5, or PDE5 inhibitors, a drug class that includes Lilly's Cialis (tadalafil), compared with those who took Cialis once a day.

May 9, 2013

Sears Holdings has appointed Jeff Balagna as EVP and chief information officer, the Kmart parent company said Thursday.

HOFFMAN ESTATES, Ill. — Sears Holdings has appointed Jeff Balagna as EVP and chief information officer, the Kmart parent company said Thursday.

Balagna was previously chief information officer for drug maker Eli Lilly and will be responsible for Sears Holdings' technology and infrastructure initiatives in its support centers and in-store.

May 2, 2013

Drug makers Boehringer Ingelheim and Eli Lilly have started a campaign designed to educate healthcare professionals about the role a type of protein plays in maintaining blood-sugar balance.

INDIANAPOLIS — Drug makers Boehringer Ingelheim and Eli Lilly have started a campaign designed to educate healthcare professionals about the role a type of protein plays in maintaining blood-sugar balance.

BI and Lilly created the website sglt.com to inform users about the role of sodium glucose co-transporters. The program also includes a video, Glucose Perspectives, in the form of a sketch animation by the United Kingdom's Royal Society for the Encouragement of Arts, Manufactures and Commerce.

April 12, 2013

Celgene Corp. chairman and CEO Robert Hugin has been elected as chairman of a pharmaceutical industry trade group.

SAN DIEGO — Celgene Corp. chairman and CEO Robert Hugin has been elected as chairman of a pharmaceutical industry trade group.

The Pharmaceutical Research and Manufacturers of America announced the election of Hugin, as well as Pfizer president and CEO Ian Read as chairman-elect of the PhRMA board of directors and Merck chairman, president and CEO as board treasurer.

Hugin succeeds Eli Lilly president, chairman and CEO John Lechleiter as chairman, PhRMA said.

 

March 25, 2013

Boehringer Ingelheim and Eli Lilly are seeking regulatory approval for an experimental drug to treat Type 2 diabetes, the companies said.

RIDGEFIELD, Conn. — Boehringer Ingelheim and Eli Lilly are seeking regulatory approval for an experimental drug to treat Type 2 diabetes, the companies said Monday.

BI and Lilly announced the submission of a regulatory application to the Food and Drug Administration for empagliflozin. The drug belongs to a new drug class known as SGLT2 inhibitors, which work by removing excess glucose through the urine by blocking its reabsorption in the kidneys. The companies are testing the drug in a late-stage clinical trial for which they plan to enroll 14,500 patients.

February 19, 2013

Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

PITTSBURGH — Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

Under the deal, Mylan will have the rights to develop and market Biocon's Glargine, Lispro and Aspart, respectively generic versions of Sanofi's Lantus, Eli Lilly's Humalog and Novo Nordisk's NovoLog.

February 8, 2013

Biotech drug maker Amgen plans to launch six biosimilar drugs starting in 2017, according to published reports.

NEW YORK — Biotech drug maker Amgen plans to launch six biosimilar drugs starting in 2017, according to published reports.

January 29, 2013

Eli Lilly and Company reported that its fourth quarter revenue for the period ended Dec. 31 declined 1% to $6 billion because of its Zyprexa patent expiration. Full-year 2012 revenue declined 7% to $22.6 billion.

INDIANAPOLIS — Eli Lilly and Company on Tuesday reported that its fourth quarter revenue for the period ended Dec. 31 declined 1% to $6 billion because of its Zyprexa patent expiration. Full-year 2012 revenue declined 7% to $22.6 billion.

November 2, 2012

Eli Lilly is spending $140 million to expand its insulin manufacturing plant in Indianapolis, the drug maker said.

INDIANAPOLIS – Eli Lilly is spending $140 million to expand its insulin manufacturing plant in Indianapolis, the drug maker said.

Lilly said it would expand the plant by 80,000 sq. ft., saying it represented one of the most significant investments in its U.S. manufacturing operations in the past decade. Construction is expected to start immediately, with completion planned for March 2014.

October 3, 2012

A drug marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly reduced blood sugar in elderly patients with Type 2 diabetes and in adults with diabetic nephropathy, according to results of three studies presented at a diabetes meeting in Berlin.

INDIANAPOLIS — A drug marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly reduced blood sugar in elderly patients with Type 2 diabetes and in adults with diabetic nephropathy, according to results of three studies presented at a diabetes meeting in Berlin.

September 26, 2012

Global flavorings leader McCormick named Eli Lilly executive Jacques Tapiero to its board.

SPARKS, Md. — Global flavorings leader McCormick named Eli Lilly executive Jacques Tapiero to its board.

Tapiero has served as SVP and president of emerging markets for Lilly since 2009 and brings more than 25 years of international business experience to the $3.5 billion spice company. Tapiero currently leads Lilly's business strategy in many of the world's fastest-growing markets, such as China, Russia, Brazil, Mexico, South Korea and Turkey. He is a member of Lilly's executive committee.

September 14, 2012

Drug makers Boehringer Ingelheim and Eli Lilly have created a new online educational program for people with Type 2 diabetes.

INDIANAPOLIS — Drug makers Boehringer Ingelheim and Eli Lilly have created a new online educational program for people with Type 2 diabetes.

The companies, which have had a deal to develop drugs for diabetes since January 2011 and co-market the drugs Tradjenta (linagliptin) and Jentadueto (linagliptin and metformin), announced Thursday the creation of My Well Planner, a lifestyle-improvement program for adults with the disease.

August 30, 2012

Eli Lilly announced that Michael Harrington will be promoted to SVP and general counsel, effective Jan. 1, 2013.

INDIANAPOLIS — Eli Lilly announced that Michael Harrington will be promoted to SVP and general counsel, effective Jan. 1, 2013.

Harrington — who currently serves as VP and deputy general counsel for the drug maker and is responsible for the legal function across Lilly's five business units — will replace Robert Armitage, who will retire at the end of the year. In his new role, Harrington will report to Lilly chairman, president and CEO John Lechleiter and will serve on the company's executive committee.

August 30, 2012

Drug maker Eli Lilly has partnered with nationally recognized health literacy experts to implement new standards to ensure the company's patient communications and resources adhere to health literacy principles.

INDIANAPOLIS — Drug maker Eli Lilly has partnered with nationally recognized health literacy experts to implement new standards to ensure the company's patient communications and resources adhere to health literacy principles.

August 29, 2012

Eli Lilly has ceased ongoing clinical studies of an investigational treatment for schizophrenia.

INDIANAPOLIS — Eli Lilly has ceased ongoing clinical studies of an investigational treatment for schizophrenia.

The drug maker said that after recently conducting an independent futility analysis, it concluded that the second of Lilly's two pivotal studies "was unlikely to be positive in its primary efficacy endpoint if enrolled to completion." Additionally, the recently completed phase-2 study, which investigated pomaglumetad methionil (also known as mGlu2/3) as an adjunctive treatment with atypical antipsychotics, did not meet its primary endpoint.

August 7, 2012

A biotech drug made by Eli Lilly for osteoporosis appeared no more or less effective than a pharmaceutical drug available as a generic in treating women with related bone fractures, but was more effective in some other measures, according to results of a late-stage clinical trial released Tuesday.

INDIANAPOLIS — A biotech drug made by Eli Lilly for osteoporosis appeared no more or less effective than a pharmaceutical drug available as a generic in treating women with related bone fractures, but was more effective in some other measures, according to results of a late-stage clinical trial released Tuesday.

July 12, 2012

A clinical trial of a drug for schizophrenia did not yield the desired results, the drug's developer said.

INDIANAPOLIS — A clinical trial of a drug for schizophrenia did not yield the desired results, the drug's developer said.

Eli Lilly announced results of the H8Y-MC-HBBM study of pomaglumetad methionil, for patients with acute exacerbation of schizophrenia. The company said results did not show the drug produced a significantly different effect from the placebo.

July 9, 2012

The Food and Drug Administration has approved a drug made by Eli Lilly and Bristol-Myers Squibb for treating a form of colorectal cancer, the two companies said.

NEW YORK — The Food and Drug Administration has approved a drug made by Eli Lilly and Bristol-Myers Squibb for treating a form of colorectal cancer, the two companies said.

Lilly and Bristol announced the approval of Erbitux (cetuximab) for treating colorectal cancer that is KRAS mutation-negative, expresses the epidermal growth factor receptor and has spread to other parts of the body, also known as metastasis. The drug is approved for use alongside a chemotherapy combination containing irinotecan, 5-fluorouracil and leucovorin, also known as FOLFIRI.

July 6, 2012

Eli Lilly announced that it has met Food and Drug Administration requirements for pediatric exclusivity for its antidepressant medication.

INDIANAPOLIS — Eli Lilly announced that it has met Food and Drug Administration requirements for pediatric exclusivity for its antidepressant medication.

Based on this decision by the FDA, Lilly has gained an additional six months of U.S. market exclusivity for Cymbalta (duloxetine hydrochloride), which now will expire in December 2013.

June 25, 2012

Teva has launched a generic version of an Eli Lilly drug.

JERUSALEM — Teva has launched a generic version of an Eli Lilly drug.

The drug maker said it has launched olanzapine and fluoxetine capsules in the 6-mg/25-mg, 12-mg/25-mg, 6-mg/50-mg, and 12-mg/50-mg strengths. The drug is a generic version of Symbyax, an acute treatment of treatment-resistant depression and bipolar I depression in adults.

Symbyax had annual sales of approximately $82 million in the United States, according to on IMS sales data.